Sarepta Therapeutics Reports Q1 2026 Earnings
Sarepta Therapeutics (SRPT) reported Q1 2026 earnings with total net product revenue of $331 million and total revenue of $731 million, a 2% decrease year-over-year. The company highlighted a 21% decrease in cost of sales and a gross margin of 82%, driven by lower sales volume.
Topics: cost restructuring financial results GAAP non-GAAP operating profit revenue